Caradon Therapeutics, Inc.

ENCINITAS, CA · Founded 2023 · Biotech · Private

Long-acting peptide-based therapeutics for cardiometabolic diseases

Claim this profile

Follows are private to you and power your alerts

Updated · caradon.bio

Sector
Biotech
Headquarters
ENCINITAS, CA
Founded
2023
Latest Form D
$559K, Feb 2026
Total capital
$559K
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$559K
1 Form D · last Feb 2026
9 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
0
1 pending

Capital timeline

2026FEDERAL ↑EQUITY ↓Cumulative $559K1st Form D$559K
2026FEDERAL ↑EQUITY ↓Cumulative $559K1st Form D$559K

Latest events

  • Private capital raisedForm D · SEC · 1st filing$559K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Founders and team

From SEC Form D filings
  • Brian Laurence JohnsonExecutive Officer, DirectorNamed in SEC Form D filings

What it has protected

USPTO · 0 granted of 1
  • PendingModified Urocortin 3USPTOApplication PCTUS2025017925

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .